Open AccessAn efficient method to prepare T cell receptor gene‐transduced cytotoxic T lymphocytes type 1 applicable to tumor gene cell‐therapy
Author(s) -
Tsuji Takemasa,
Chamoto Kenji,
Funamoto Hiromi,
Kosaka Akemi,
Matsuzaki Junko,
Abe Hiroyuki,
Fujio Keishi,
Yamamoto Kazuhiko,
Kitamura Toshio,
Togashi Yuji,
Koda Toshiaki,
Nishimura Takashi
Publication year - 2003
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2003.tb01452.x
Subject(s) - cytotoxic t cell , cd8 , t cell receptor , interleukin 2 , microbiology and biotechnology , antigen , biology , cytotoxicity , interleukin 21 , t cell , cytokine , cancer research , immunology , in vitro , immune system , biochemistry
Genes encoding 2C T cell receptor (TCR) α, β chains from H‐2 b ‐re‐stricted L d ‐specific CD8 + cells were successfully transduced into polyclonally activated CD8 + cells by retroviral modification to generate antigen‐specific cytotoxic T lymphocytes (CTL). Antigen‐nonspecific CD8 + T cells polyclonally expanded in the presence of interleukin (IL)‐2, Th1 cytokines (interferon (IFN)‐γ and IL‐12) and anti‐IL‐4 monoclonal antibody showed neither cytokine production nor cytotoxicity in response to L d ‐expressing P815 tumor cells. However, 2C‐TCR gene‐modified CD8 + T cells exhibited both IFN‐γ production and cytotoxicity in response to P815 tumor cells. The antitumor activity of TCR gene‐modified Tc1 cells was also demonstrated in vivo by Winn's assay. Thus, we have developed an efficient method to induce TCR gene‐modified antigen‐specific Tc1 cells that exhibit antitumor activity both in vitro and in vivo . (Cancer Sci 2003; 94: 389–393)